PPT-PCSK9 Inhibition: LDL Lowering

PCSK9 inhibitors New option for dyslipidemia Alireza EsteghamatiMD November 2018 Agenda Residual risk after Statin PCCSK9 Inhibitors physiology amp mechanism of action PCSK9 Inhibitor trials . 1 Competitive Inhibition Fig 8- 2 Competitive InhibitionCTEuli S + S E P + E c = K . ( [ c / K c / Vx sl re S bu i n a S bd t fee E a a s wre S bd c w S f fee E S the Understanding . of . Cholesterol Metabolism:. The Role of Proprotein Convertase . Subtilisin/. K. exin . Type 9 (PCSK9) . in the Regulation of Low-Density Lipoprotein Cholesterol (LDL-C) and LDL . Type 9 (PCSK9). Implications for Low-Density Lipoprotein Cholesterol (LDL-C). © . 2014 . Amgen Inc. All rights reserved. Not for Reproduction. . USA-145-100024(1). PCSK9 Mutations Are Involved in Familial Hypercholesterolemia. of Cholesterol Metabolism:. The Role of . Proprotein. . Convertase. . Subtilisin. -like/. kexin. Type 9 (PCSK9) . in the Regulation of Low-Density Lipoprotein Cholesterol (LDL-C) and LDL . Receptors (LDL-Rs). Physiology, pathophysiology and treatments. Under the supervision of Dr.. . Mezei. . Zsófia. Leticia . Szadai. , . Philomène. . Toquet. and Erwan Williamson. Introduction . WHO : Prevalence of raised blood cholesterol, age : 25+ . Victor Nadler. Objectives. By the end of this class, students will be able to. :. Explain the role of dietary lipids and endogenous lipoproteins, including dietary cholesterol, chylomicrons, VLDL-C, LDL-C, and . CGR 0800 h 11 May 2015. Rob Hegele MD FRCPC FACP. Distinguished Professor of Medicine and Biochemistry. Western University. London, Canada. hegele@robarts.ca. Financial disclosure: speaker and ad board member for . Lowering Sodium without Losi ng Flavor Union Public Schools Tulsa, Oklahoma Lisa Griffin, RD, LD Callie Fowler- Farish Director of Child Nutrition District Executive Chef Union Public Schools-Tulsa, OK John Kastelein, MD . Academic Medical Centre. Amsterdam, The Netherlands. Slides. . prepared. and . presented. . by. At CV Risk . master. classes 2013. 2. Novel Approaches to Modify . Lipids and Lipoproteins. Brian A. . Ference. MD, . MPhil. , . MSc. , John J. P. Kastelein MD, PhD, . Kausik. K. Ray MD, . MPhil. , Henry N. Ginsberg MD, M. John Chapman PhD, . DSc. , Chris J. Packard . DSc. , Ulrich . Laufs. Publication about . this. . research. : . Y. Zhang, M. . Ultsch. , N. Skelton, S. Burdick, M. . Beresini. , W. Li, M. Kong-Beltran, A. Peterson, J. Quinn, C. Chiu, Y. Wu, S. Shia, P. Moran, P. Di . Lello. Which ONE of the following statements regarding the mechanism of action of PCSK9 inhibitors is CORRECT?. a. Reduced hepatic production of LDL-C by inhibition of ATP citrate lyase. b. Increased LDL receptor (LDLR) surface density via increase in LDLR recycling and reduced LDLR degradation. AMVAC Chemical Corporation. FMC Corporation. Gowan. Company. September 15-18, 2020. Outline of Presentation. Introduction to Testing Program (Rick Reiss) – 15 minutes. Experimental Procedures and Results (Jan Chambers) – 20 minutes. DB09302. Description. :. Alirocumab. is a biopharmaceutical drug approved by the FDA in July 2015 as a second line treatment for high cholesterol for adults whose LDL-cholesterol (LDL-C) is not controlled by diet and statin treatment. It is a human monoclonal antibody administered by subcutaneous injection that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood.